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With the widespread clinical use of comparative genomic hy-
bridization chromosomal microarray technology, several pre-
viously unidentified clinically significant submicroscopic
chromosome abnormalities have been discovered. Specifically,
there have been reports of clinically significant microduplica-
tions found in regions of known microdeletion syndromes. In
general, these microduplications have distinct features from
those described in the corresponding microdeletion syndromes.
We present a 51/2-year-old patient with normal growth, border-
line normal IQ, borderline hypertelorism, and speech and lan-
guage delay who was found to have a submicroscopic 2.3 Mb
terminal duplication involving the two proposed Wolf–
Hirschhorn syndrome (WHS) critical regions at chromosome
4p16.3. This duplication was the result of a maternally inherited
reciprocal translocation involving the breakpoints 4p16.3 and
17q25.3. Our patient’s features are distinct from those described
in WHS and are not as severe as those described in partial trisomy
4p. There are two other patients in the medical literature with
4p16.3 microduplications of similar size also involving the WHS
critical regions. Our patient shows clinical overlap with these two
patients, although overall her features are milder than what has
been previously described. Our patient’s features expand the
knowledge of the clinical phenotype of a 4p16.3 microduplica-
tion and highlight the need for further information about it.
 2011 Wiley-Liss, Inc.
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INTRODUCTION
With the advent of comparative genomic hybridization (CGH)
chromosomal microarray technology, several clinically significant
submicroscopic duplications in regions known to cause micro-
deletion syndromes have been identified. The features of these
microduplication syndromes are clinically distinct from the micro-
deletion syndromes that share the same regions. Some of these
include duplication of 22q11.2, the region involved in Velocardio-
facial syndrome [Portnoi, 2009], duplication of 7q11.23, the region
involved in Williams syndrome [Van der Aa et al., 2009], and
duplication of 17p11.2 (Potocki–Lupski syndrome), the region
involved in Smith–Magenis syndrome [Potocki et al., 2007].
We present a 51/2-year-old female patient with a submicroscopic
2.3 Mb terminal duplication of 4p16.3. This duplication involves
the two proposed critical regions for Wolf–Hirschhorn syndrome
(WHS), which is a well-characterized microdeletion syndrome
caused by a deletion of 4p16.3. The first critical region, called
WHSCR1, is a 165 kb area approximately 2 Mb from the telomere
of 4p and includes the genes WHSC1 and WHSC2 [Wright et al.,
1997, 1999; Stec et al., 1998]. The second critical region, called
WHSCR2, includes WHSC1 and LETM1 and is contiguous and
telomeric to WHSCR1. It is estimated to be 300–600 kb in size
positioned between 1.9 and 1.6–1.3 Mb from the telomere [Zollino
et al., 2003].
Our patient’s clinical features are distinct from those described
in WHS and are not as severe as those found in individuals with
cytogenetically detectable partial trisomy 4p [Gonzalez et al., 1977;
Patel et al., 1995; Battaglia et al., 2002]. This case provides further
information regarding the clinical significance and variability of
a microduplication of 4p16.3.
CLINICAL REPORT
Our patient was initially referred at age 4 years, 4 months for
evaluation of a mild intention tremor, speech delay, and dysmor-
phic facial features. She was born to a 26-year-old, primagravida
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female. The pregnancy was uncomplicated and there were no
teratogenic exposures. She was delivered at 40 weeks gestation
by cesarean for breech presentation. Birth weight was 2.89 kg
(10th centile); length was 47 cm (10th centile). Head circumference
and APGARS were unknown. She was diagnosed with bilateral
hip dysplasia and required a harness for 5 weeks. A cardiologist
diagnosed her as having an innocent heart murmur. She also had
a normal ophthalmology examination.
There were no concerns for her early developmental milestones.
She reportedly sat at 5 months, took her first steps at 12 months,
and spoke her first words at 9 months. There were concerns
regarding her speech pronunciation at 18 months of age. She could
speak two word phrases at approximately 21/2–3 years of age. Her
developmental assessment at 31/2 years of age showed delays in
her communication skills as well as mild delays in her gross and fine
motor skills. She had been evaluated by a neurologist for a mild
intention tremor. Developmental delay was noted but no specific
cause for the tremor was identified. Our physical examination at age
4 years, 4 months showed: weight 15.8 kg (50th centile); height
99.0 cm (25th centile), and head circumference 49.5 cm (just<50th
centile). She had borderline hypertelorism with an intercanthal
distance of 3.25 cm (90th centile). There were no other dysmorphic
features (Fig. 1). Neurologic examination was negative; we did
not notice the intention tremor. Karyotype was normal female
46,XX.
The patient was seen for a follow-up visit at 51/2 years of age. In
addition to the above, she had developed pubic hair at 5 years of age.
An endocrine evaluation was normal. Her bone age was found to be
between 7 years, 10 months and 8 years, 10 months which is
advanced in comparison to her chronologic age of 5 years, 7 months
at the time of the evaluation. She also had a reported history of
polyuria/polydipsia and night-time intermittent urinary inconti-
nence. Her serum electrolytes were normal. She had WPPSI-III
performed at 51/2 years of age which showed a full scale IQ of 80;
verbal IQ of 80; performance IQ of 88. She was found to have
poor adaptive behavior, poor communication, and moderate-to-
severe delays in receptive and expressive speech. On physical
examination, weight was 20.2 kg (50th–75th centile); height was
105 cm (10th centile), and head circumference was 50.5 cm
(50th centile). Her facial features were unchanged. Her breast
development was at Tanner stage I. There was slight dark pubic
hair over the labia majora. Her neurologic examination showed no
abnormality.
The patient’s younger sister presented to us at the same time as
our patient at 5 months of age for an initial evaluation for failure
to thrive. The sister’s evaluation was unremarkable aside from the
failure to thrive. The sister presented again at 21 months, at the
same time as our patient, with failure to thrive and the additional
findings of developmental delay and a new onset of seizures. At
this follow-up visit, we drew the sister’s blood for chromosomal
microarray analysis.
Family history was remarkable for a 40-year-old maternal great
aunt who reportedly has short stature, intellectual disability, and
seizures of unknown etiology.
METHODOLOGY AND RESULTS
Oligonucleotide aCGH
Oligonucleotide-based microarray analysis was performed using
a 105K-feature whole-genome microarray (SignatureChip Oligo
Solution, designed by Signature Genomic Laboratories (Spokane,
WA) and Agilent Technologies (Santa Clara, CA) and made by
Agilent Technologies) as previously described [Ballif et al., 2008].
Our patient’s sister was found to have the following result: arr
4p16.3(35,881–2,297,002)x1,17q25.3(78,323,289–78,637,842)x3.
This resulted in a terminal deletion at 4p16.3 which was approxi-
mately 2.3 Mb in size and a terminal duplication at 17q25.3 which
was approximately 314.6 kb in size. The 4p16.3 deletion involves
both WHSCR1 and WHSCR2 (Figs. 2 and 3).
Fluorescence In Situ Hybridization (FISH)
Analysis
Metaphase FISH analysis was performed using BAC clones RP11-
478C6 and RP11-46H21 to visualize the abnormalities as previously
described [Traylor et al., 2009]. These results confirmed that the
sister’s abnormality was the result of an unbalanced translocation
between 4p16.3 and 17q25.3. This abnormality, together with the
sister’s clinical features, confirmed a diagnosis of WHS in her.
FIG. 1. Our patient at 6-year old. She has borderline hypertelorism
but otherwise has no notable dysmorphic features. [Color figure
can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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Following the sister’s results, metaphase FISH analysis was
performed on the mother and then subsequently on our patient.
The mother’s FISH results detected a balanced translocation
between 4p16.3 and 17q25.3 (Fig. 4). Our patient was detected
as having the reciprocal version of the unbalanced translocation,
namely a terminal duplication at 4p16.3 and a terminal deletion
at 17q25.3 (Fig. 5). Thus far, no other family members have
been tested for the presence of this translocation.
FIG. 2. Microarray characterization of the unbalanced translocation resulting in deletion of 4p16.3 and a duplication of 17q25.3 in the sister of our
patient. (1) Microarray plot showing a single-copy loss of 149 oligonucleotide probes from the short arm of chromosome 4 at 4p16.3
(chr4:35,881–2,297,002, hg 18 assembly), approximately 2.3 Mb in size. Probes are ordered on the x-axis according to physical mapping positions,
with the most distal p-arm probes to the left and the most distal q-arm probes to the right. (2) Microarray plot showing a single-copy gain of 37
oligonucleotide probes from the long arm of chromosome 17 at 17q25.3 (chr17:78,323,289–78,637,842) approximately 315 kb in size. Probes are
ordered as in 1. Results are visualized using Genoglyphix software (Signature Genomics). [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
FIG. 3. Graphical representation of the regions involved in the translocation. Purple box: Chromosome 4p region. Pink box: Chromosome 17q region. Red
and green boxes: Wolf–Hirschhorn critical region. Blue boxes: OMIM genes. Gray boxes: Other genes in region. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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DISCUSSION
We present a case of a submicroscopic duplication of 4p16.3
involving the WHS critical regions. This case is clinically distinct
from both WHS and the trisomy 4p syndrome. The classic clinical
features of WHS include prenatal and postnatal growth retardation,
intellectual disability, seizures, and distinctive dysmorphic facial
features described as a ‘‘Greek warrior helmet’’ facies [Battaglia
et al., 2008]. Our patient does not have any of these classic features
and there is very little clinical overlap of her features with WHS.
Trisomy 4p is a distinct clinical entity that has been described
in more than 75 cases. In general, patients are trisomic for at least
the distal 2/3 of 4p. Clinical features include growth retardation,
psychomotor retardation, cardiac anomalies, and renal anomalies.
The dysmorphic features include a prominent glabella, bulbous
nose with a flat nasal bridge, retrognathia, abnormal ears, and
rocker bottom feet [Gonzalez et al., 1977; Patel et al., 1995].
There have been several patients with trisomy 4p described in the
medical literature that have documented involvement of the WHS
loci, however, almost all cases have been cytogenetically detectable
duplications, and, therefore, larger than the duplication present
in our case [Cotter et al., 2001; Tschernigg et al., 2002; Gerard-
Blanluet et al., 2004; Takeno et al., 2004; Bartocci et al., 2008]. Our
patient has none of the severe features described in these patients.
Thus far, there have been only two other cases in the medical
literature with submicroscopic duplications of 4p involving the
WHS critical regions. Rosello et al. [2009] describe a 10-year-old
boy who was found to have a 1.1 Mb duplication involving the WHS
critical regions. However, he also had a 1.3 Mb distal deletion of 4p.
It has been suggested that a deletion distal to the WHS critical
regions may be responsible for seizures, developmental delay,
and growth retardation seen in some patients with a ‘‘mild’’ WHS
phenotype [South et al., 2008]. Therefore, his phenotype may not be
solely explained by his duplication of 4p.16.3. However, there
still is clinical overlap between our case and this patient including
hypertelorism, normal height, and developmental delay most
significant in speech (Table I).
More recently, Hannes et al. [2010] presented a 15-month-old
child with a 560 kb interstitial duplication of 4p16.3 also involving
the WHS critical regions. He additionally was found to have an
inversion between 4p16.3 and 4q22. His clinical features are much
more significant than our patient and the patient presented by
Rosello et al. [2009] and include a hand malformation, hypotonia,
glaucoma of the left eye, and development at a 5-month old level
(Table I). Given the severity of his features, it is possible that his
inversion may be affecting his phenotype in some way, possibly by
a gene disruption of some kind.
Our patient, in addition to the terminal duplication of 4p16.3,
has a 314.6 kb deletion of 17q25.3. Thus far, there have not been
any cases in the medical literature with a deletion of 17q25.3 of this
size causing a clinically significant phenotype. In fact, there has been
some evidence to suggest that a deletion of 17q25.3 is a benign copy
number variant [Balikova et al., 2007]. There are only four genes
in the 17q25.3 region. Tubulin-specific chaperone D (TBCD) has
been found to be expressed in brain tissue [Nagase et al., 1999]. Zinc
finger protein 750 (ZNF750) has been found to be expressed in
several tissues including human keratinocytes but not in the brain
[Birnbaum et al., 2006]. Beta 3N-acetyleglucosaminyltransferase
(B3GNTL1) was isolated from fetal brain cDNA but was found to be
expressed most significantly in the adult pancreas [Zheng et al.,
2004]. And finally, Meteorin (METRNL) is thought to be involved
in neurogenesis and in angiogenesis at the glialvascular interface
[Nishino et al., 2004; Park et al., 2008]. Despite the fact that 3 of
FIG. 4. FISH in the mother showing a reciprocal translocation
between 4p16.3 and 17q25.3. (1) FISH showing derivative 17
(long arrow) with presence of signal from BAC clone RP11-478C6
from the 4p16.3 region (labeled in red) and derivative 4 (short
arrow) with absence of signal from clone RP11-478C6. (2) FISH
showing derivative 4 (short arrow) with presence of signal from
BAC clone RP11-46H21 from the 17q25.3 region (labeled in red)
and derivative 17 (long arrow) with absence of signal from
RP11-46H21. In both panels, chromosome 4 centromere probe
D4Z1 and chromosome 17 centromere probe D17Z1 are labeled in
green as controls. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
FIG. 5. FISH in patient showing a derivative chromosome 17 with a
duplication of 4p16.3 and a deletion of 17q25.3. (1) FISH showing
derivative 17 (arrow) with presence of signal from BAC clone
RP11-478C6 from the 4p16.3 region, labeled in red. (2) FISH
showing derivative 17 (arrow) with absence of signal from BAC
clone RP11-46H21 from the 17q25.3 region, labeled in red. In both
panels, chromosome 4 centromere probe D4Z1 and chromosome
17 centromere probe D17Z1 are labeled in green as controls. [Color
figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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these 4 genes are expressed in the brain, there is no information
indicating if haploinsufficiency of any of these genes is sufficient to
cause a clinically significant phenotype. However, we cannot rule
out the possibility that the deletion at 17q25.3 could be contributing
to our patient’s phenotype.
Our patient’s case illustrates several important concepts. She
presents with a relatively mild phenotype when compared to other
individuals with a duplication of 4p16.3. Her mild phenotype
suggests that there may be wide variability of the features associated
with this duplication. Additionally, our case helps provide prog-
nostic information regarding microduplications in general. Our
patient’s phenotype is milder than what has been described in WHS
even in those cases involving small deletions of 4p16.3 <3.5 Mb
[Zollino et al., 2008]. Therefore, our patient’s case provides further
evidence that, in general, microduplications are better tolerated
than microdeletions of the same region. Additionally, our patient
provides further evidence of the pathogenic nature of copy
number changes in areas known to involve dosage-sensitive genes.
It has been suggested that the same dosage-sensitive genes known
to be pathogenic when haploinsufficient in microdeletion syn-
dromes may cause different phenotypic consequences if they are
over-expressed. Portnoi [2009] suggests that over-expression of
TBX1 (a major gene associated with the Velocardiofacial/Digeorge
syndrome phenotype) may be the cause of the 22q11.2 micro-
duplication syndrome. Potocki et al. [2007] has proposed that the
RAI1 gene (a gene thought to be causative in Smith–Magenis
syndrome) may be responsible for the features of Potocki–Lupski
syndrome when over-expressed. While our single case does not
help us identify which of the genes in the WHS critical regions
may be responsible for our patient’s phenotype, it suggests
that there may be genes in the region that are sensitive to over-
expression.
In conclusion, our patient’s case helps expand the understanding
of the nature of pathogenic microduplications in general. Addi-
tionally, it provides evidence that a microduplication of 4p16.3
involving the WHS critical regions causes a clinically relevant
phenotype, likely with extreme variability. It also highlights the
need for further research on pathogenic microduplications involv-
ing dosage-sensitive genes in general and more specifically on the
emerging phenotype associated with a microduplication of 4p16.3.
ACKNOWLEDGMENTS
We would like to thank Signature Genomics, Inc. for providing the
figures and testing methodology and the family for their assistance
with publishing this case.
REFERENCES
Balikova I, Menten B, de Ravel T, Le Caignec C, Thienpont B, Urbina
M, Doco-Fenzy M, de Rademaeker M, Mortier G, Kooy F, van Den
Ende J, Devriendt K, Fryns JP, Speleman F, Vermeesch JR. 2007.
Subtelomeric imbalances in phenotypically normal individuals. Hum
Mutat 28:958–967.
Ballif BC, Theisen A, McDonald-McGinn DM, Zackai EH, Hersh JH,
Bejjani BA, Shaffer LG. 2008. Identification of a previously unrecognized
microdeletion syndrome of 16q11.2q12.2. Clin Genet 74:469–475.
Bartocci A, Striano P, Mancardi MM, Fichera M, Castiglia L, Galesi O,
Michelucci R, Elia M. 2008. Partial monosomy Xq(Xq23-qter) and
trisomy 4p(4p15.33-pter) in a woman with intractable focal epilepsy,
TABLE I. A Comparison of Our Patient to Two Patients in the Literature
Features Our patient Rosello et al. [2009] Hannes et al. [2010]
4p16.3 duplication size 2.3 Mb 1.1 Mb 560 kb
4p16.3 duplication location 35,881–2,297,002 Approx. 1,300,000–2,400,000 1,458,385–1,907,425





Age 51/2 years 9
1/2 years 15 months
Height Normal Normal Not reported
Weight 50th centile <11th centile <3rd centile
Speech delay Yes Yes Yes
Full scale IQ 80 Not reported Not reported
Developmental delay Yes Yes Yes




Epicanthic folds No Yes Yes
Low set/abnormal ears No Yes Yes













CARMANY AND BAWLE 823
borderline intellectual functioning, and dysmorphic features. Brain Dev
30:425–429.
Battaglia A, Brothmann AR, Carey JC. 2002. Recombinant 4 syndrome due
to an unbalanced pericentric inversion of chromosome 4. Am J Med
Genet 112:103–106.
Battaglia A, Filippi T, Carey J. 2008. Update on the clinical features and
natural history of Wolf–Hirschhorn (4p) syndrome: Experience with
87 patients and recommendations for routine health supervision. Am J
Med Genet Part C 148C:246–251.
Birnbaum RY, Zvulunov A, Hallel-Halevy D, Cagnano E, Finer G, Ofir R,
Geiger D, Silberstein E, Feferman Y, Birk OS. 2006. Seborrhea-like
dermatitis with psoriasiform elements caused by a mutation in ZNF750,
encoding a putative C2H2 zinc finger protein. Nature Genet 38:749–751.
Cotter PD, Kaffe S, Li L, Gershin IF, Hirschhorn K. 2001. Loss of
subtelomeric sequence associated with a terminal inversion duplication
of the short arm of chromosome 4. Am J Med Genet 102:76–80.
Gerard-Blanluet M, Romana S, Munier C, Le Lorc’h M, Kanafani S, Sinico
M, Touboul C, Levaillant JM, Haddad B, Lopez N, Lelong F, Billette de
Villemeur T, Verloes A, Borghi E. 2004. Classical West ‘‘syndrome’’
phenotype with a subtelomeric 4p trisomy. Am J Med Genet Part A 130A:
299–302.
Gonzalez CH, Sommer A, Meisner LF, Elejalde BR, Opitz JM. 1977.
The trisomy 4p syndrome: Case report and review. Am J Med Genet
1:137–156.
Hannes F, Drozniewska M, Vermeesch JR, Haus O. 2010. Duplication of the
Wolf–Hirschhorn syndrome critical region causes neurodevelopmental
delay. Eur J Med Genet 53:136–140.
Nagase T, Ishikawa K, Suyama M, Kikuno R, Hirosawa M, Miyajima N,
Tanaka A, Kotani H, Nomura N, Ohara O. 1999. Prediction of the coding
sequences of unidentified human genes. XIII. The complete sequences of
100 new cDNA clones from brain which code for large proteins in vitro.
DNA Res 6:63–70.
Nishino J, Yamashita K, Hashiguchi H, Fujii H, Shimazaki T, Hamada H.
2004. Meteorin: A secreted protein that regulates glial cell differentiation
and promotes axonal extension. EMBO 23:1998–2008.
Park JA, Lee HS, Ko KJ, Park SY, Kim JH, Choe GY, Kweon HS, Song HS,
Ahn JC, Yu YS, Kim KW. 2008. Meteorin regulates angiogenesis at the
gliovascular interface. Glia 56:247–258.
Patel S, Dagnew H, Parekh A, Koenig E, Conte R, Macera M, Verma R. 1995.
Clinical manifestations of trisomy 4p syndrome. Eur J Pediatr 154:
425–431.
Portnoi MF. 2009. Microduplication 22q11.2: A new chromosomal syn-
drome. Eur J Med Genet 52:88–93.
Potocki L, Bi W, Treadwell-Deering D, Carvalho CMB, Eifert A, Friedman
EM, Glaze D, Krull K, Lee JA, Lewis RA, Mendoza-Londono R, Robbins-
Furman P, Shaw C, Shi X, Weissenberger G, Withers M, Yatsenko SA,
Zackai EH, Stankiewicz P, Lupski JR. 2007. Characterization of
Potocki–Lupski syndrome (dup(17)(p11.2p11.2)) and delineation of a
dosage-sensitive critical interval that can convey an autism phenotype.
Am J Hum Genet 80:633–649.
Rosello M, Monfort S, Orellana C, Ferrer-Bolufer I, Quiroga R, Oltra S,
Martınez F. 2009. Submicroscopic duplication of the Wolf–Hirschhorn
critical region with a 4p terminal deletion. Cytogenet Genome Res 125:
103–108.
South ST, Hannes F, Fisch GS, Vermeesch JR, Zollino M. 2008.
Pathogenic significance of deletions distal to the currently described
Wolf–Hirschhorn syndrome critical regions on 4p16.3. Am J Med Genet
Part C 148C:270–274.
Stec I, Wright TJ, van Ommen GJ, de Boer PA, van Haeringen A, Moorman
AF, Altherr MR, den Dunnen JT. 1998. WHSC1, a 90kb SET domain-
containing gene, expressed in early development and homologous to a
Drosophila dysmorphy gene maps in the Wolf–Hirschhorn syndrome
critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol
Genet 7:1071–1082.
Takeno SS, Corbani M, Andrade JAD, Smith MAC, Brunoni D, Melaragno
MI. 2004. Duplication 4p and deletion 4p (Wolf–Hirschhorn syndrome)
due to complementary gametes from a 3:1 segregation of a maternal
balanced t(4;13)(p16;q11) translocation. Am J Med Genet Part A 129A:
180–183.
Traylor RN, Fan Z, Hudson B, Rosenfeld JA, Shaffer LG, Torchia BS, Ballif
BC. 2009. Microdeletion of 6q16.1 encompassing EPHA7 in a child with
mild neurological abnormalities and dysmorphic features: Case report.
Mol Cytogenet 2:17.
Tschernigg M, Petek E, Wagner K, Kroisel PM. 2002. Mild phenotype due
to inverse duplication 4p16.3—p15.3 including the Wolf–Hirschhorn
critical region. Genet Couns 13:29–33.
Van der Aa N, Rooms L, Vandeweyer G, Van den Ende J, Reyniers E, Fichera
M, Romano C, Delle Chiaie B, Mortier G, Menten B, Destree A, Maystadt
I, Mannik K, Kurg A, Reimand T, McMullan D, Oley C, Brueton L,
Bongers EMHF, Van Bon BWM, Pfund R, Jacquemont S, Ferrarini A,
Martinet D, Schrander-Stumpel C, Stegmann APA, Frints SGM, De Vries
BBA, Ceulemans B, Kooy RF. 2009. Fourteen new cases contribute to the
characterization of the 7q11.23 microduplication syndrome. Eur J Med
Genet 52:94–100.
Wright TJ, Ricke DO, Denison K, Abmayr S, Cotter PD, Hirschhorn K,
Kein€anen M, McDonald-McGinn D, Somer M, Spinner N, Yang-Feng
T, Zackai E, Altherr MR. 1997. A transcript map of the newly defined
165kb Wolf–Hirschhorn syndrome critical region. Hum Mol Genet
6:317–324.
Wright TJ, Costa JL, Naranjo C, Francis-West P, Altherr MR. 1999.
Comparative analysis of a novel gene from the Wolf–Hirschhorn/Pitt-
Rogers-Danks syndrome critical region. Genomics 59:203–212.
Zheng H, Lia Y, Ji C, Li J, Zhang J, Yin G, Xu J, Ye X, Wu M, Zou X, Gu S, Xie
Y, Mao Y. 2004. Characterization of a cDNA encoding a protein with
limited similarity to b1, 3-N-acetylglucosaminyltransferase. Mol Biol
Rep 31:171–175.
Zollino M, Lecce R, Fischetto R, Murdolo M, Faravelli F, Selicorni A, Butte
C, Memo L, Capovilla G, Neri G. 2003. Mapping the Wolf–Hirschhorn
syndrome phenotype outside the currently accepted WHS critical region
and defining a new critical region, WHSCR-2. Am J Hum Genet 72:
590–597.
Zollino M, Murdolo M, Marangi G, Pecile V, Galasso C, Mazzanti L, Neri G.
2008. On the nosology and pathogenesis of Wolf–Hirschhorn syndrome:
Genotype–phenotype correlation analysis of 80 patients and literature
review. Am J Med Genet Part C 148C:257–269.
824 AMERICAN JOURNAL OF MEDICAL GENETICS PART A
